Bay Cat vs

Catopuma badia compared with Clitopilus passeckerianus

Key Differences

• Bay Cat is Endangered while is Not Evaluated.

Taxonomic Classification

Rank	Bay Cat
Kingdom	Animalia (Animals)	Fungi (Fungi)
Phylum	Chordata (Chordates)	Basidiomycota (Club Fungi)
Class	Mammalia (Mammals)	Agaricomycetes (Mushrooms)
Order	Carnivora (Carnivorans)	Agaricales (Gilled Mushrooms)
Family	Felidae (Cats)	Entolomataceae
Genus	Catopuma	Clitopilus
Species	Catopuma badia	Clitopilus passeckerianus

Conservation Status

Bay Cat

EN — Endangered

NE — Not Evaluated

Physical Characteristics

Attribute	Bay Cat
Diet	—	—
Average Lifespan	—	—
Average Length	—	—
Average Weight	—	—

Habitat & Geographic Range

Bay Cat

Habitat

Typically found in diverse terrestrial and aquatic ecosystems.

Habitat

Typically found in forest floors, decomposing wood, and soil ecosystems.

Range

Distributed across Norway and Sweden.

Bay Cat

The Bay Cat (Catopuma badia) is a species in the genus Catopuma. It is currently classified as Endangered on the IUCN Red List. Typically found in diverse terrestrial and aquatic ecosystems.

Clitopilus passeckerianus is a white-rot agaric fungus in the family Entolomataceae notable for its role as a natural producer of pleuromutilin, a diterpenoid antibiotic compound that serves as the biosynthetic precursor for the veterinary and human antibiotic drugs tiamulin and valnemulin, used to treat Mycoplasma infections in livestock. First described from European woodland habitats, the species produces the characteristic Clitopilus fruiting body: a pale, whitish cap with decurrent, crowded gills becoming pinkish at maturity from angular spores, and a farinaceous odor. Its antibiotic-producing capacity makes C. passeckerianus of significant pharmaceutical interest, and biosynthetic studies of pleuromutilin production have informed synthetic chemistry approaches to antibiotic development. The species inhabits temperate deciduous woodland floors in Europe, fruiting in autumn among leaf litter. Discovery of its pleuromutilin biosynthetic pathway has opened avenues for heterologous expression and semi-synthetic modification aimed at developing novel antibiotics to counter antibiotic-resistant bacterial pathogens.